Clinical Trials Sponsored by National Cancer Institute, Egypt

Total 22113 results

National Cancer Institute (NCI)

Completed

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Biliary Cancer

United States
National Cancer Institute (NCI)

Completed

Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

Melanoma | Lymphoma | Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

M7824 in Subjects With HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Human Papilloma Virus | Vaginal or Penile Cancer

United States
National Cancer Institute (NCI)

Completed

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Pancreatic Cancer | Cholangiocarcinoma | Colon Cancer | Liver Metastasis | Metastatic Colon Carcinoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic | Lymphoma, Extranodal NK-T-Cell | Enteropathy-Associated T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s

Neuroendocrine Tumors | Carcinoma, Neuroendocrine

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Adrenocortical Carcinoma | Adrenocortical Cancer

United States
National Cancer Institute (NCI)

Completed

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Sarcoma, Kaposi | Kaposi Sarcoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib for Advanced Urothelial Cancer

Kidney Neoplasms | Urinary Bladder Neoplasms | Urothelial Carcinoma | Urethral Neoplasms

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Pazopanib and ARQ 197 for Advanced Solid Tumors

Solid Tumor

United States
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Bevacizumab for Recurrent Ependymoma

Ependymoma | Anaplastic Ependymoma

United States
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
National Cancer Institute (NCI)

Terminated

Sunitinib in Sarcomas of the Central Nervous System

Gliosarcoma | Central Nervous System Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma | Rhabdomyosarcoma, Alveolar | Rhabdomyosarcoma, Embryonal

United States
National Cancer Institute (NCI)

Terminated

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Carcinoma, Renal Cell | Gastrointestinal Stromal Tumors | Pheochromocytoma | Paraganglioma | Renal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
National Cancer Institute (NCI)

Terminated

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Melanoma | Sarcoma | Thoracic Sarcomas | Thorasic Cancers | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer | Gallbladder Cancer

United States
National Cancer Institute (NCI)

Terminated

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Mesothelioma

United States
National Cancer Institute (NCI)

Completed

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

BRCA1 Gene | BRCA2 Gene

United States
National Cancer Institute (NCI)

Terminated

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Anal Cancer

United States
National Cancer Institute (NCI)

Completed

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Subcutaneous Panniculitis-Like T-Cell Lymphoma | T-Cell Peripheral Lymphoma | Gamma Delta Hepatosplenic T-Cell Lymphoma | NK T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

NHS-IL12 for Solid Tumors

Epithelial Tumors, Malignant | Epithelial Neoplasms, Malignant | Malignant Mesenchymal Tumor

United States
National Cancer Institute (NCI)

Terminated

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Hodgkin Disease | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Number of Quit Attempts

United States
National Cancer Institute (NCI)

Completed

Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer

Bladder Cancer

United States
National Cancer Institute (NCI)

Terminated

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Cancer | Cancer of Pancreas

United States
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Completed

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
National Cancer Institute (NCI)

Completed

Risk Factors for Non-HIV-Related Kaposi s Sarcoma

Kaposi's Sarcoma

Italy
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
National Cancer Institute (NCI)

Completed

The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis

AIDS

United States
National Cancer Institute (NCI)

Completed

Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering

Normal Physiology

United States
National Cancer Institute (NCI)

Completed

Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test

Cancers

United States
National Cancer Institute (NCI)

Withdrawn

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

United States
National Cancer Institute (NCI)

Terminated

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Renal Cell Carcinoma | Renal Cell Cancer | Hereditary Leiomyomatosis

United States
National Cancer Institute (NCI)

Completed

Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States

Kidney Cancer | Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Medullary Thyroid Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Li-Fraumeni Syndrome

United States
National Cancer Institute (NCI)

Completed

Family Study of Head and Neck Cancers in Taiwan

Nasopharyngeal Neoplasms | Herpesvirus 4, Human

China
National Cancer Institute (NCI)

Completed

Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China

Lung Neoplasms

China
National Cancer Institute (NCI)

Completed

Human Papillomavirus Epidemiology in Nigeria

Cervical Intraepithelial Neoplasia | Uterine Cervical Neoplasms | Human Papillomavirus 16 | Human Papillomavirus 18

Nigeria
National Cancer Institute (NCI)

Completed

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Neoplasm

United States

Clinical Trials Sponsored by National Cancer Institute, Egypt

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations